UBS Group
XGN icon

UBS Group’s Exagen XGN Stock Holding History

UBS Group’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Sell
4,059
-23,845
-85% -$89.8K ﹤0.01% 8192
2026
Q1 		$83.7K Sell
27,904
-85,085
-75% -$329K ﹤0.01% 7079
2025
Q4 		$687K Buy
112,989
+22,978
+26% +$209K ﹤0.01% 5876
2025
Q3 		$989K Sell
90,011
-356,196
-80% -$3.15M ﹤0.01% 5582
2025
Q2 		$3.11M Buy
446,207
+383,691
+614% +$2.33M ﹤0.01% 4354
2025
Q1 		$224K Sell
62,516
-1,701
-3% -$6.42K ﹤0.01% 6475
2024
Q4 		$263K Sell
64,217
-14,310
-18% -$51.6K ﹤0.01% 6285
2024
Q3 		$243K Buy
78,527
+16,011
+26% +$41.5K ﹤0.01% 5730
2024
Q2 		$114K Hold
62,516
– – ﹤0.01% 6089
2024
Q1 		$99.4K Buy
62,516
+107
+0.2% +$208 ﹤0.01% 6231
2023
Q4 		$124K Sell
62,409
-68,424
-52% -$118K ﹤0.01% 6055
2023
Q3 		$317K Hold
130,833
– – ﹤0.01% 5011
2023
Q2 		$379K Hold
130,833
– – ﹤0.01% 5045
2023
Q1 		$318K Sell
130,833
-6,015
-4% -$15.6K ﹤0.01% 5031
2022
Q4 		$328K Buy
136,848
+35
+0% +$90 ﹤0.01% 5044
2022
Q3 		$370K Buy
136,813
+5,144
+4% +$28.7K ﹤0.01% 4595
2022
Q2 		$756K Sell
131,669
-298
-0.2% -$1.74K ﹤0.01% 3953
2022
Q1 		$1.06M Sell
131,967
-3,824
-3% -$33K ﹤0.01% 4038
2021
Q4 		$1.58M Buy
135,791
+5,892
+5% +$69K ﹤0.01% 3951
2021
Q3 		$1.77M Buy
129,899
+678
+0.5% +$9.01K ﹤0.01% 3675
2021
Q2 		$1.94M Sell
129,221
-3,342
-3% -$51.2K ﹤0.01% 3607
2021
Q1 		$2.32M Buy
132,563
+131,703
+15,314% +$2.35M ﹤0.01% 3413
2020
Q4 		$11K Buy
860
+815
+1,811% +$11.5K ﹤0.01% 7433
2020
Q3 		$0 Sell
45
-1,466
-97% -$18.9K ﹤0.01% 8454
2020
Q2 		$19K Sell
1,511
-415
-22% -$5.62K ﹤0.01% 6598
2020
Q1 		$31K Sell
1,926
-2,163
-53% -$42.9K ﹤0.01% 6191
2019
Q4 		$104K Buy
+4,089
New +$72.8K ﹤0.01% 5983

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

UBS Group's XGN Position: Q2 2026 in Review

UBS Group reduced its Exagen (XGN) stake by 85% in Q2 2026, selling an estimated $89.8K and leaving 4,059 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8192.

UBS Group first reported a position in XGN in Q4 2019 and has held it in 27 quarters since. The position peaked at $3.11M in Q2 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • UBS Group held 4,059 shares of Exagen worth $18.9K as of Q2 2026.
  • UBS Group sold 23,845 Exagen shares in Q2 2026, an estimated $89.8K.
  • Exagen made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8192 holding.
  • UBS Group first reported a position in Exagen in Q4 2019 and has held it in 27 quarters since.
  • UBS Group's Exagen position peaked at $3.11M in Q2 2025.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.